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ABSTRACT* 
Background: Evidence suggests that patients with 
type 2 diabetes (T2DM) suffer from a high rate of 
“clinical inertia” or “recognition of the problem but 
failure to act.”  
Objective: The aim of this study is to quantify the 
rate of clinical inertia between two models of care: 
Pharmacist-Managed Diabetes Clinic (PMDC) vs. 
Usual Medical Care (UMC). 
Methods: Patients in a university based medical 
clinic with type 2 diabetes (T2DM) were analyzed in 
this retrospective cohort study. Patients were 
exposed to either PMDC or UMC. The difference in 
days to intervention in response to suboptimal 
laboratory values and time to achieve goal 
hemoglobin A1c (A1c), systolic blood pressure 
(SBP) and low-density lipoprotein (LDL) was 
compared in the two models of care.  
Results: A total of 113 patients were included in the 
analysis of this study, 54 patients were in the PMDC 
and 59 patients were in the UMC group. Median 
time (days) to intervention for A1c values >7% was 
8 days and 9 days in the PMDC and UMC groups, 
respectively (p>0.05). In patients with baseline A1c 
values >8%, median time to achieving A1c<7% was 
259 days vs. 403 days in the PMDC and UMC 
groups, respectively (p<0.05). Median time to goal 
SBP was 124 days in the PMDC group and 532 
days in the UMC group (p<0.05). Median time to 
goal LDL was 412 days in the PMDC group vs. 506 
days in the UMC group (p<0.05).  
Conclusions: Rates of clinical inertia, defined as 
time to intervention of suboptimal clinical values, did 
not differ significantly between patients enrolled in a 
PMDC compared to patients with UMC with respect 
to A1c, SBP and LDL. Participation in PMDC, 
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INERCIA CLÍNICA EN DIABETES TIPO 2: 
ANÁLISIS RETROSPECTIVO DE 
CUIDADOS DIABÉTICOS POR 
FARMACÉUTICOS CONTRA CUIDADOS 
MÉDICOS HABITUALES 
 
RESUMEN 
Antecedentes: La evidencia sugiere que los 
pacientes con diabetes tipo 2 (T2DM) padecen 
elevada “inercia clínica” o “reconocimiento del 
problema pero fracaso en la actuación”.  
Objetivo: El objetivo de este estudio es cuantificar 
la tasa de inercia clínica entre dos modelos de 
cuidados: consulta de diabetes gestionada por 
farmacéutico (PMDC) vs. cuidados médicos 
habituales (UMC). 
Métodos: Se analizó en este estudio de cohorte 
retrospectiva a los pacientes con diabetes tipo 2 de 
una clínica médica universitaria. Los pacientes 
estuvieron expuestos a PMDC o a UMC. Se 
comparó la diferencia entro los dos modelos de 
cuidados en días desde la intervención en la 
respuesta a los valores sub-óptimos de laboratorio y 
el tiempo en alcanzar los objetivos de hemoglobina 
A1c (A1c) presión arterial sistólica (SBP) y 
lipoproteínas de baja densidad (LDL). 
Resultados: Se incluyó en el análisis de este 
estudio a un total de 113 pacientes, 54 en el grupo 
PMDC y 59 en el UMC. La mediana de tiempo 
(días) desde la intervención para valores de A1c 
>7% fue de 8 y 9 días en los grupos PMDC y 
UMC, respectivamente (p>0,05). En los pacientes 
con A1c basal>8%, la mediana de tiempo para 
alcanzar una A1c<7% fue de 259 días vs. 403 días 
en los grupos PMDC y UMC, respectivamente 
(p<0,05). El tiempo medio hasta el objetivo de SBP 
fue de 124 días en el grupo PMDC y 532 en el 
UMC (p<0,05). La mediana de tiempo para el 
objetivo de LDL fue de 412 días en el grupo PMDC 
vs. 506 días en el UMC (p<0,05). 
Conclusiones: Las tasas de inercia clínica, 
definidos como el tiempo desde la intervención de 
valores clínicos sub-óptimos, no difirieron 
significativamente entre los pacientes incluidos en 
un PMDC comparados con pacientes en UMC en 
relación a A1c, SBP y LDL. Sin embargo, la 
participación en un PMDC estuvo asociado con 
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INTRODUCTION 
Intensification of therapy in a timely manner and 
compliance with evidence based standards of care 
in patients with type 2 diabetes (T2DM) remains 
suboptimal despite strong clinical evidence that 
continues to support reduction in both 
macrovascular and microvascular damage in 
diabetes patients with optimal glycemic control.1 
Despite recent conflicting data from the ACCORD 
(Action to Control Cardiovascular Risk in Diabetes) 
study2, evidence still suggests that patients continue 
to derive benefit from intensive glycemic control, 
particularly in the early course of disease 
progression, prior to development of co-
morbidities.3 Current American Diabetes 
Association (ADA) guidelines recommend targeting 
pre-prandial plasma glucose 90-130 mg/dL, 
postprandial plasma glucose <180 mg/dL and 
glycosylated hemoglobin (A1c) <7%.4 Guidelines 
from the American College of Endocrinology (ACE) 
target even lower goals in select patients: pre-
prandial glucose less than 110 mg/dL, postprandial 
glucose <140 mg/dL and A1c <6.5%.5 Despite well-
established therapeutic goals, treatment of T2DM 
continues to fall short.  
In an effort to improve care and achieve glycemic 
goals in patients with T2DM, researchers have 
sought to identify characteristics of primary care 
models that contribute to lack of optimization and 
failure to achieve treatment targets in patients with 
chronic disease. Clinical inertia is a term used to 
describe the current lack of timely intervention and 
treating to targets among patients with chronic 
disease states. Phillips and colleagues define 
clinical inertia as “recognition of the problem, but 
failure to act”.6 By this definition, clinical inertia is 
not a patient-centered problem but a problem of the 
health care system. A recent study evaluated 
primary care and specialist care in an attempt to 
characterize clinical inertia in each cohort of 
patients.7 The results of this trial revealed that less 
than 50% of patients in both groups had drug 
intensification in response to suboptimal A1c values 
(A1c>8%).  
Studies have quantified the rate of clinical inertia in 
several different practice settings to include 
academic medical centers and Veterans Affairs 
(VA) hospitals.8 Grant and colleagues recently 
demonstrated low rates of medical regimen change 
among a consortium of academic medical centers 
across the United States. The incidence of 
medication optimization in patients with A1c above 
goal was approximately 40%. Rates of optimization 
remained less than 50% even among patients who 
had reported A1c’s of >9%. Among untreated 
patients, few with elevated blood pressure (10.1% 
with blood pressure >130/80 mmHg) or elevated 
LDL cholesterol (5.6% with LDL >100 mg/dL) were 
initiated on therapy. 
While the rate of clinical inertia has been published, 
no studies have quantified clinical inertia as a 
function of time. In this study we sought to quantify 
clinical inertia as a function of time and compare 
clinical inertia between two different models of care, 
a usual medical care model (UMC) and a 
pharmacist-managed diabetes clinic (PMDC), which 
was centered on dedicated patient visits with a 
Pharmacist in addition to the usual medical care a 
patient would normally receive. Collaborative care 
models with Pharmacists have demonstrated 
improved outcomes in patients with chronic 
diseases, such as diabetes.9,10 Johnson and 
colleagues demonstrated a mean A1c reduction of 
3.6%, in patients with baseline A1c >10%, who 
were enrolled in a pharmacist-based diabetes 
clinic.11 We hypothesized that these improved 
outcomes could be attributed to a difference in 
clinical inertia or time to intervention of suboptimal 
A1c values. 
 
METHODS  
A retrospective cohort analysis was performed in 
patients who were a part of a university-based 
primary care clinic. These patients were separated 
into two cohorts depending on their exposure to 
usual medical care (UMC) or a pharmacist-
managed diabetes clinic (PMDC). Details of this 
pharmacist-managed diabetes clinic have been 
published elsewhere.12 But briefly, the PMDC 
program consists of patients referred by their 
primary care providers who attend a 1-hour 
individual assessment and then group diabetes 
education classes that follow the ADA-
recommended curricula. After completion of the 
classes, patients follow-up with a pharmacist every 
one to three months for medication therapy 
management and education reinforcement. In 
individual sessions, medication adherence, 
medication changes, behavioral goals, ADA 
standards of care, vital signs, weight, disease 
complications, primary care provider-ordered 
laboratory values, and self-monitoring of glucose 
results are assessed. Sensory monofilament exams 
and point-of-care hemoglobin A1c and lipid panels 
are performed when appropriate.  
At the time of this study, pharmacists in this clinic 
did not have the authority to prescribe or adjust 
medication therapy. Instead, each visit with the 
pharmacist was summarized and documentation 
was sent along with any recommendations for 
improved disease management to the patient’s 
health care providers. Patients who were a part of 
the PMDC also kept routine appointments with their 
primary care providers, who were aware that they 
were part of a pharmacist-managed diabetes clinic. 
Pharmacist recommendations from diabetes visits 
were flagged on the medical record for review 
during each patient visit with his or her primary care 
physician. 
All study patients had a diagnosis of T2DM, were 
greater than 17 years of age at time of diagnosis, 
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and received care by one of two practice models, 
pharmacist-managed diabetes clinic (PMDC) or 
usual medical care (UMC). Patients in the PMDC 
were included if they attended the initial 
assessments, three education classes and at least 
two visits to the PMDC. Inclusion criteria also 
included having at least three primary outcome 
measures (A1c) in the time period measured, 
between March 2003 and December 2005. These 
patients were identified using the PMDC patient 
database.  
Usual medical care (UMC) patients were included in 
the analysis if they were diagnosed as incident 
T2DM patients between January 1st 2000 and June 
30th 2005. Incident patients did not have a diagnosis 
of diabetes or a prescription for any anti-diabetic 
medication in the six months prior to diagnosis. 
Inclusion criteria for the UMC group included: data 
supporting that the diagnosis and treatment 
decisions were made by a primary care practitioner 
in the study clinic, at least two visits to the study 
clinic, at least three primary outcome measures 
(A1c) in the time period, and lack of enrollment in 
the PMDC program. Patients were identified from 
the university healthcare plan database using the 
primary diagnosis code as the reason for the visit 
(ICD-9 code of 250.xx (Diabetes Mellitus).  
In each cohort, data was collected using 
standardized chart review forms for the study period 
and entered into the research database. For the 
UMC group, data from chart review included the 
dates January 2000 through December 2005. Data 
for the PMDC group included only data from the 
medical record and did not include PMDC clinic 
chart data. This was done to assess the 
effectiveness of using chart notes to communicate 
information between clinics. A clinic visit was 
defined as a visit to a physician, nurse practitioner, 
or pharmacist. The following variables were 
assessed: any A1c, lipid panel, recorded blood 
pressure measurement and diabetes-related 
intervention during the defined study period. An 
intervention was defined as the documented 
performance of any of the following: intensification 
of medication, addition of medication, diet/exercise 
counseling, medication counseling, referral, or 
disease state management education.  
Statistical Analysis 
The primary outcome in this study was time to 
intervention (days) for suboptimal A1c levels (>7%). 
For each suboptimal laboratory value, the number 
of days between reporting of laboratory value and 
documented intervention in the patients’ medical 
record was recorded. For each of the three 
diabetes-related risk factors: A1c, systolic blood 
pressure (SBP), low-density lipoprotein (LDL), the 
changes in corresponding medical regimens 
throughout the course of the study period was 
recorded. Treatment goals were derived from 
evidence-based national standards published by the 
American Diabetes Association (ADA). Additionally, 
medication change rates were stratified at different 
thresholds for A1c (>8%), SBP (>130 mmHg) and 
LDL (>130 mg/dL).  
Chi-square and Fisher’s exact tests were used to 
compare categorical data between groups as 
appropriate. Other continuous data were compared 
using Student’s t-tests and Wilcoxon rank sum tests 
as appropriate. The primary endpoint of interest is 
the time to interventions. To compare the difference 
in days to endpoint between UMC and PMDC 
groups, Kaplan-Meier curves were created for the 
probability of achieving goal A1c, goal LDL and goal 
SBP over time. An estimated hazard ratio was 
calculated with a 95% confidence interval using the 
Cox proportional hazard regression in order to 
summarize the effect of type of care given on time 
to intervention. STATA version 11.1 (StataCorp, 
College Station, TX, USA) was used for all analyses 
and P<0.05 was taken to indicate statistical 
significance.  
 
RESULTS  
A total of 120 patients were identified from the 
PMDC database that had T2DM and were actively 
enrolled in the pharmacist-managed diabetes clinic 
program. From this population, 54 (45%) patients 
met inclusion criteria for the PMDC cohort. In the 
UMC group, 1300 patients with a diagnosis of 
diabetes were identified, of which 59 (4.5%) patients 
met inclusion criteria for the control group. There 
were 1,241 patients excluded during data 
abstraction because chart information showed they 
had long-standing diabetes or A1c data was 
insufficient to be included in the study. Table 1 
summarizes the demographic information, baseline 
medications and baseline A1c groupings for each 
cohort. Baseline A1c values were not statistically 
different between groups. 
Table 2 summarizes the analysis of A1c values. 
Among those A1c values that were not at goal, 55% 
prompted intervention in the PMDC group 
compared to 52% in the UMC group (p>0.05). 
Compared to the UMC group, the PMDC group did 
Table 1. Patient Characteristics 
Total population (n, %) PMDC (n=54) 
UMC 
(n=59) 
Sex* 
   Female 
   Male 
 
35 (64.8) 
19 (35.2) 
 
22 (37.3) 
37 (62.7) 
Mean age (SD)* 50.1 (10.1) 44.1 (9.4) 
Ethnicity 
   Asian 
   African-American 
   Caucasian 
   Other 
 
2 (3.7) 
13 (24.1) 
37 (68.5) 
2 (3.7) 
 
2 (3.5) 
12 (20.6) 
40 (69.0) 
4 (6.9) 
Diabetes Therapy 
 Diet and Exercise Only* 
 Monotherapy Oral 
 Combination Oral  
 Combination Oral Insulin* 
 
2 (3.7) 
22 (40.7) 
23 (42.6) 
6 (11.1) 
 
12 (20.3) 
27 (45.8) 
19 (32.2) 
0 
Initial A1C grouping 
    <7% 
    7-7.9% 
    8-8.9%  
    > 9% 
 
32 (59.2) 
8 (14.8) 
3 (5.6) 
11 (20.4) 
 
29 (49.2) 
15 (25.4) 
7 (11.8) 
8 (13.6) 
Grouping from initial systolic BP 
    <130 mmHg 
    130-159.9 mmHg 
    ≥160 mmHg 
 
18 (40.9) 
24 (54.6) 
2 (4.5) 
 
15 (25.9) 
36 (62.1) 
7 (12.0) 
*statistically different at p-value ≤0.05 
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not differ in clinical inertia or median days to 
intervention in response to a suboptimal lab value 
(p>0.05). The overall median time to goal relative to 
initial A1c groupings also did not differ in the PMDC 
group compared with the UMC group, 227 days vs. 
250 days (p>0.05), respectively. In patients with 
baseline A1c>8%, patients in the PMDC group who 
achieved goal A1c<7% did so by a median of 144 
days sooner (p<0.05). Kaplan-Meier survival 
analysis used to assess the probability of patients 
achieving goal A1c over time did not reveal any 
overall differences between groups, hazard ratio, 
1.00 (95%CI, 0.99-1.00) (Figure 1). When isolating 
only those patients that begin the study at A1c>=8, 
the Cox regression was still not significant (HR 0.80, 
95%CI 0.18-3.51; p=0.766).  
Systolic blood pressure (SBP) and LDL were also 
assessed in both study populations. These results 
are summarized in Tables 3 and 4. Patients in both 
groups had low rates of medication intervention 
(addition or dose optimization) in response to SBP 
readings not at goal, 8% and 18%, in the PMDC 
group vs. UMC, respectively. Due to inconsistent 
documentation of intervention in response to 
elevated blood pressure readings, we were unable 
to report median days to intervention in response to 
SBP readings. Patients in the PMDC group who 
reached goal SBP (<130 mm Hg), however, did so 
by a median of 408 days sooner compared to UMC 
patients who reached goal SBP (p<0.05). When 
compared with patients in the UMC group, patients 
in the PMDC group also had a higher probability of 
achieving goal SBP (<130 mm Hg) earlier in the 
course of therapy although this hazard ratio did not 
reach statistical significance (HR 2.21, 95%CI 0.63-
7.76) (Figure 2).  
In comparison to A1c and SBP interventions, higher 
rates of intervention were seen in response to 
elevated LDL-C levels, 13% of patients in the 
PMDC group and 16% in the UMC group. Median 
time to intervention for LDL levels above goal did 
not differ between the two groups (p>0.05). 
However, in patients who achieved goal LDL, 
median time to goal (days) was significantly shorter 
in the PMDC group (412 days vs. 506 days, 
p<0.05). The Kaplan-Meier curve shows no 
difference in probability of achieving goal over time 
between the two groups (HR 0.73 95%CI 0.25-2.13) 
(Figure 3). 
 
DISCUSSION 
This is the first study to our knowledge that 
quantifies the rate of clinical inertia by measuring 
the number of days between obtaining suboptimal 
clinical values and subsequent intervention. 
Furthermore, we chose to characterize clinical 
inertia among two different models of care in order 
to provide an additional explanation for improved 
outcomes associated with pharmacist-based 
collaborative care models.9,11,13 We found no 
difference in time to intervention of suboptimal A1c 
values between PMDC and UMC. When patients 
with baseline A1c values >8% were analyzed, 
however, patients in the PMDC group had 
significantly shorter time to achieving goal 
compared to the UMC group. 
The data demonstrated that patients who have a 
higher baseline A1c benefited from early, intensive 
pharmacist-based diabetes intervention. These 
findings also suggest that other factors besides 
clinical inertia are responsible for the significant 
reductions in A1c and other diabetes related risk 
factors (SBP and LDL) that have been reported with 
this pharmacist-managed diabetes clinic program.11 
The original hypothesis proposed that lower rates of 
clinical inertia in the PMDC group would explain 
Table 2. Interventions for A1c≥7% (each patient can have more than 1 intervention for more than 1 A1c value) 
Variable PMDC UMC 
Number of A1c values ≥7%  148 194 
    Of these, how many had an interventions 83 (56) 101 (52) 
Median number of days to intervention 8 (1-475) 9 (1-372) 
Median days to intervention by A1C range 
     7-7.9% 
     8-8.9% 
     > 9% 
 
8 (1-475) 
7 (3-251) 
22 (2-363) 
 
7 (1-293) 
29 (2-372) 
25 (1-225) 
Median time to goal A1C (range) a 227 (99-1362) 250 (20-1778) 
Median time to goal by initial A1C group 
    ≤7-7.9 
    >8% b 
 
329 (99-1362) 
259 (99-960) 
 
195 (2-941) 
403 (31-1778) 
a the first reading <7% A1C was considered at goal 
b statistically different at p-value ≤0.05 
Table 3. Table of systolic blood pressures (SBP) 
Variable (n, %) PMDC UMC 
Total population (n=102) 44  58  
Number of systolic  BP values ≥130 327 572 
Interventions performed 
    Dose optimization* 
    Add a drug* 
    Patient education* 
  
16 (4.9) 
11 (3.4) 
5 (1.5) 
  
53 (9.3) 
49 (8.6) 
30 (13.4) 
Median time (days) to intervention Data not consistently reported on date on when intervention occurred  
Number of patients reaching goal systolic d   9  23 
Median time (days) to goal (range)* d 124 (35-947) 532 (31-1778) 
*statistically different at p-value ≤0.05 
d Two consecutive systolic BP readings ≤130 mmHg 
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improved outcomes. However, results from this trial 
demonstrated no difference in clinical inertia, yet 
significant differences were detected in the time to 
achieve goal, favoring patients in the PMDC group. 
This suggests that measuring time to achieving goal 
measures may be a better predictor of positive 
outcomes compared to time to intervention. 
Results from the analysis of secondary outcomes in 
this study further support this theory. Patients in the 
PMDC group had a higher probability of achieving 
SBP goals when compared to UMC patients and 
shorter time (days) to achieving goal SBP and LDL 
levels when compared to UMC. Patients in the 
PMDC group achieved goal SBP nearly eight 
months sooner and achieved goal LDL over two 
months sooner compared to UMC patients. In the 
absence of differences in time to intervention, these 
improvements may be attributed to diabetes related 
education and reinforcement of disease state 
management through lifestyle modification and 
medication adherence. This finding further supports 
the impact of pharmacist-provided diabetes 
education on achieving ADA goals.  
Although not specifically evaluated in our study, we 
suspect that patients enrolled in the PMDC group 
had greater adherence to prescribed therapy and 
lifestyle interventions as a result of their 
participation in the pharmacist-managed diabetes 
program. These “treatment” or pharmacist-
intervention effects may have led to the findings of 
improved SBP and LDL outcomes seen in this 
study. Other studies have also demonstrated the 
link between pharmacist education, medication 
adherence and outcomes.14 The effects of these 
types of interventions are more detectable in near-
term and can be measured given the immediate 
effects of medication adherence and lifestyle 
modification on parameters such as blood pressure 
and lipid profile. 
The PMDC program consisted of a combination of 
appropriate nutrition, physical activity and 
preventative screening. These factors are 
underscored through the promotion of diabetes self-
management, which is an ongoing, education 
process that included the following: 1) assessment 
of the individual’s specific education needs; 2) 
identification of the individual’s specific diabetes 
self-management goals; 3) education and 
behavioral intervention directed toward helping the 
individual achieve identified self-management goals; 
4) evaluation of the individual’s attainment of 
identified self-management goals.15 In a meta-
analysis conducted by the Centers for Disease 
Control (CDC), patient self-management education 
was effective in improving outcomes in patients with 
diabetes.14 Results from our study corroborate with 
these findings.  
This retrospective analysis identified systematic 
program issues that may have affected the results 
of this study. At the time of the study pharmacists in 
our program did not have the authority to adjust 
medications but they were aggressive in providing 
disease state education and medication counseling 
to improve medication adherence. Following each 
visit, a complete note with recommendations from 
the pharmacist was written and sent to the patients’ 
primary care physician for review. In a separate 
published analysis of this PMDC, DeName and 
colleagues found that the median time of 2 weeks 
elapsed before the healthcare provider in this 
Table 4. Table of LDL levels 
Variable (n, %) PMDC UMC 
Total population (N=77) 27  50 
Grouping from initial LDL 
  <70 
  70-99.9 
  100-129.9 
  130-159.9 
  ≥160 
  
2 (7) 
10 (37) 
9 (33) 
4 (15) 
2 (7) 
  
6 (12) 
13 (26) 
10 (20) 
18 (36) 
3 (56) 
Number of lab values with 
LDL≥100 127  164  
Interventions performed 
    Dose optimization 
    Add a drug 
    Patient education* 
  
7 (5.5) 
9 (7.1) 
1 (0.8) 
  
6 (3.7) 
21 (12.8) 
27 (16.5) 
Median time (days) to 
intervention 7 (1-322) 8 (1-343) 
Number of patients reaching goal 
LDL f 12 20 
Median time (days) to goal 
(range)* 
412  
(119-553) 
506  
(77-1508) 
*statistically different at p-value ≤0.05 
f the first reading LDL 100 is considered at goal LDL 
Figure 1. Kaplan-Meier curves for the probability of 
achieving goal A1C   
Figure 2. Kaplan-Meier curve for the probability of 
achieving Goal SBP  
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practice setting accepted a clinical medication 
recommendation.16 Moreover, the acceptance rate 
of clinical recommendations made to the provider 
was 60.2%. The inability to actively modify patient 
treatment regimens within the PMDC had an impact 
on clinical inertia as defined in our study and in 
some cases; this model may have contributed to 
clinical inertia.  
In retrospect, if pharmacists had the ability to take 
action at the point of care, clinical inertia may have 
been significantly reduced based on the days 
lapsed between patient clinic visits with the 
pharmacist and the primary care provider. Although 
the time to medication optimization was not different 
between PMDC and UMC, patients in the PMDC 
group received instant feedback and education from 
pharmacists who helped motivate patients to 
achieve target goals. Findings from this study 
suggest that targeted patient education programs 
can improve outcomes in patients with diabetes, 
independent of the rates of medication optimization 
or time to intervention.  
Another potential source of bias identified was the 
differences between patient groups identified at 
baseline. In an effort to reduce selection bias, we 
identified patients who were newly diagnosed in the 
UMC group in order to match the intensity of 
treatment patients received in the PMDC group. It 
was assumed that patients who were newly 
diagnosed were more likely to receive initial 
diabetes education, performance of ADA standards 
of care, and medication initiation compared to those 
patients who have long-standing diabetes. Selecting 
incident cases of T2DM in the UMC group may 
have led to an unfavorable comparison since 
patients in the PMDC group had long-standing 
T2DM and may have had long-standing issues with 
adherence to treatment or clinic visits that were not 
identified. This may have biased the results of the 
study towards not detecting a difference in time to 
intervention. 
As a potential source of information bias, it should 
also be noted that the average time of enrollment 
for patients in the pharmacist-managed diabetes 
clinic group was 612 days or 1.7 years. The data for 
these patients were collected from their initial 
enrollment to their most recent clinic visit even 
though patients may have stopped being seen by 
the PMDC group. Patients had the option to dis-
enroll from the program after meeting initial 
requirements. Following dis-enrollment, patients 
maintained their visits with their primary care 
provider in internal medicine. Data collection 
continued under the planned intention to treat 
analysis. As a result, these patients who were 
engaged with PMDC for a limited period of time 
would likely have less benefit from being a part of 
the program. Comparatively, patients in the UMC 
group had increased exposure time due to the 
average duration of follow-up, which was five years.  
Despite these biases and the limitations inherent in 
retrospective analyses, this study demonstrates the 
impact of pharmacist-based diabetes management 
on improving outcomes in patients with T2DM. 
Clinical inertia and the rates of medication 
optimization in patients with T2DM should remain 
an important quality measure evaluated among 
organizations. Evidence still supports intensive early 
treatment of patients with new onset diabetes to 
limit disease progression and to slow the decline of 
beta cell function.17 Medication therapy is critical in 
this early stage to reduce insulin resistance and 
prevent the detrimental effects of prolonged 
hyperglycemia. Despite questionable support for 
intensive glycemic control to reduce macrovascular 
events, analysis of ACCORD data continues to 
demonstrate the benefit of intensive glycemic 
control in reducing microvascular event rates.2 
These affects seem to be magnified when treating 
patients earlier in their course of disease and prior 
to developing additional co-morbidities.  
This project expands upon the initial results of the 
PMDC program by identifying a link between 
improved outcomes and disease state management 
by pharmacists. Despite the inability to detect a 
significant difference in clinical inertia rates, 
significant improvements in outcomes were 
detected. Methods to counteract clinical inertia, 
however, are still needed to improve quality of care 
and ultimately outcomes related to diabetes. 
Pharmacists can play a pivotal role in improving the 
quality of care diabetes patients receive and 
counteracting clinical inertia through patient 
education. This can occur through structural and 
organizational changes in clinical practice that allow 
for early screening, detection and management of 
suboptimal diabetes control before the onset of 
morbidity and mortality related to diabetes.  
Optimizing collaborative disease state management 
programs between pharmacists and providers 
remain essential to combating clinical inertia. The 
American Society of Health-System Pharmacists 
(ASHP) recently launched the Pharmacy Practice 
Model Initiative (PPMI), which seeks to redefine the 
way pharmacists practice within the health-system 
to provide direct patient care that maximizes their 
potential for impact.18 Results from this study further 
support this initiative in that it demonstrates the 
impact that regulatory and scope of practice 
limitations has on pharmacists’ ability to act as 
direct care providers to improve patient outcomes. 
Figure 3. Kaplan-Meier curve for the probability of 
achieving goal LDL  
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These limitations, which vary widely between states, 
can impact the effectiveness pharmacists have on 
reducing rates of clinical inertia. 
 
CONCLUSIONS 
Despite evidence demonstrating improved patient 
outcomes, a pharmacist-managed diabetes clinic 
model without authority to adjust medication therapy 
or order laboratory tests according to approved 
collaborative practice agreements, did not reduce 
clinical inertia or time to intervention of suboptimal 
laboratory values when compared to UMC. 
However, significant improvements in time to 
achieving goal A1c, SBP and LDL was detected in 
high-risk groups. Based on findings from this study, 
we suggest that pharmacist-managed diabetes 
clinics seek to obtain collaborative care agreements 
with their physician partners that allow for 
medication adjustments and ordering of routine 
laboratory tests. These agreements should be 
evidence based and mutually agreed upon with their 
supervising physician. Reducing clinical inertia in 
diabetes rests in the ability to make timely decisions 
and take immediate action when responding to 
patient clinical outcomes that are not at goal. 
Diabetes education continues to be an important 
tool in the treatment arsenal and should augment 
any strategy to reduce clinical inertia and improve 
patient outcomes. Further studies are needed to 
establish the impact of pharmacist-based diabetes 
management on patient adherence and outcomes. 
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